A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

September 30, 2024

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

HB1801

HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.

DRUG

Taxotere

Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.

Trial Locations (1)

RECRUITING

Jilin Provincial Tumor Hospital, Changchun

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY